Piper Sandler Maintains Overweight on Ardelyx, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 87.4%

Neg 87.4% Neu 0% Pos 0%

Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Overweight and lowers the price target from $16 to $15.